Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001047469-19-006979
Filing Date
2019-12-31
Accepted
2019-12-31 16:46:54
Documents
13
Effectiveness Date
2019-12-31

Document Format Files

Seq Description Document Type Size
1 DEFM14A a2240376zdefm14a.htm DEFM14A 5878657
2 G495934.JPG g495934.jpg GRAPHIC 10872
3 G628112.JPG g628112.jpg GRAPHIC 7589
4 G793643.JPG g793643.jpg GRAPHIC 11037
5 G795792.JPG g795792.jpg GRAPHIC 103545
6 G869776.JPG g869776.jpg GRAPHIC 111172
7 G816992.JPG g816992.jpg GRAPHIC 107177
8 G503235.JPG g503235.jpg GRAPHIC 72567
9 G998563.JPG g998563.jpg GRAPHIC 93347
10 G301648.JPG g301648.jpg GRAPHIC 128788
11 G310488.JPG g310488.jpg GRAPHIC 6695
12 G264812MMI001.GIF g264812mmi001.gif GRAPHIC 87332
13 G264812MMI002.GIF g264812mmi002.gif GRAPHIC 49973
  Complete submission text file 0001047469-19-006979.txt   6969700
Mailing Address 435 DEVON PARK DRIVE, SUITE 715 WAYNE PA 19087
Business Address 435 DEVON PARK DRIVE, SUITE 715 WAYNE PA 19087 610-254-4201
Aevi Genomic Medicine, Inc. (Filer) CIK: 0001138776 (see all company filings)

EIN.: 980217544 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-35112 | Film No.: 191319879
SIC: 2836 Biological Products, (No Diagnostic Substances)